*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**AIM Vaccine Co., Ltd.**
**艾美疫苗股份有限公司**
*(a joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock Code: 06660)**

# VOLUNTARY ANNOUNCEMENT
# COMPLETION OF THE LAYOUT OF ITERATIVE RABIES VACCINE PRODUCTS AND FULLY ADVANCING THE RESEARCH AND DEVELOPMENT OF THE PRODUCT SERIES

This announcement is made by AIM Vaccine Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to inform shareholders and potential investors of the Company of the latest business developments of the Group.

Following its established corporate strategy, the Group proactively advances the development of its vaccine pipelines and accelerates the research and development of the iterative rabies series vaccines through on-going technological innovation, achieving new productive forces at an accelerated pace. As the second largest supplier of rabies vaccine globally, the Group has expedited the development of iterative rabies series vaccines, in particular: 1. the on-site work of the phase III clinical trial of iterative serum-free rabies vaccine has been completed, and various preparatory work for the new drug application is underway, which is planned to be completed in 2024; 2. the pre-application for clinical trial for the novel-process human diploid rabies vaccine is expected to be submitted in the first half of 2024; 3. the iterative mRNA rabies vaccine is the first non-COVID-19 mRNA vaccine candidate accepted by relevant authorities in China.

Completely unlike the existing Vero cell rabies vaccine containing serum and human diploid rabies vaccine containing serum, the iterative serum-free rabies vaccine is an iterative product. Animal serum residues in vaccine products are one of the important factors leading to adverse reactions such as allergies in vaccinated populations, and the iterative serum-free rabies vaccine developed by the Group does not contain animal serum, which significantly improves safety and reduces the probability of adverse reactions. To date, there is no serum-free rabies vaccine approved for launch in the global market.

The novel-process human diploid rabies vaccine developed by the Group became the first to break through the technical bottleneck of low virus titer and small yield in the traditional process, with optimized and innovated purification process, which has notably improved product quality and safety as compared with similar marketed products in China, and has the production capacity for large-scale commercialization.

In the meantime, the Group's mRNA technology platform has been tested by the clinical trial data from tens of thousands of subjects, and the iterative mRNA rabies vaccine has been developed on such platform. Such vaccine is the first non-COVID-19 mRNA vaccine accepted by the Center for Drug Evaluation for its clinical trial application, and has been proven by a massive number of animal tests. The vaccine is characterized by markedly decreased number of vaccinations, significantly accelerated the pace of protective neutralizing antibodies generation and remarkably enhancing comprehensive protective effect as compared with the traditional virus-cultured rabies vaccine.

The Group has completed the construction of its workshops for iterative serum-free rabies vaccine and novel-process human diploid rabies vaccine, which have sufficient production capacity and meet international standards, and the equipment is currently being debugged and verified. As the second largest supplier of rabies vaccines globally, the Group spearheads the in-depth technological iteration of rabies vaccines in the world, and will deliver rabies vaccine products with better quality and higher safety in the market after the above iterative rabies series vaccines are marketed, so that new productive forces will be achieved in the industry.

By order of the Board
**AIM Vaccine Co., Ltd.**
**Mr. Yan ZHOU**
*Chairman of the Board, Executive Director and Chief Executive Officer*

Hong Kong, March 4, 2024

*As at the date of this announcement, the Board of the Company comprises Mr. Yan ZHOU, Mr. Wen GUAN and Mr. Shaojun JIA as executive directors; Mr. Jie ZHOU, Mr. Xin ZHOU, Mr. Jichen ZHAO and Ms. Aijun WANG as non-executive directors; and Professor Ker Wei PEI, Mr. Xiaoguang GUO, Ms. Jie WEN and Mr. Hui OUYANG as independent non-executive directors.*